WO2007118986A3 - Concentre d'immunoglobulines et de fragments f(ab) '2 et /ou fab specifiques d'un arbovirus en tant que medicament - Google Patents

Concentre d'immunoglobulines et de fragments f(ab) '2 et /ou fab specifiques d'un arbovirus en tant que medicament Download PDF

Info

Publication number
WO2007118986A3
WO2007118986A3 PCT/FR2007/000560 FR2007000560W WO2007118986A3 WO 2007118986 A3 WO2007118986 A3 WO 2007118986A3 FR 2007000560 W FR2007000560 W FR 2007000560W WO 2007118986 A3 WO2007118986 A3 WO 2007118986A3
Authority
WO
WIPO (PCT)
Prior art keywords
arbovirus
immunoglobulins
concentrate
fab fragments
medicine
Prior art date
Application number
PCT/FR2007/000560
Other languages
English (en)
Other versions
WO2007118986A2 (fr
WO2007118986A8 (fr
Inventor
Roland Schmitthaeusler
Original Assignee
Lab Francais Du Fractionnement
Roland Schmitthaeusler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement, Roland Schmitthaeusler filed Critical Lab Francais Du Fractionnement
Priority to EP07731238A priority Critical patent/EP2004229A2/fr
Priority to JP2009502154A priority patent/JP2009531400A/ja
Priority to AU2007239414A priority patent/AU2007239414A1/en
Priority to CA002647504A priority patent/CA2647504A1/fr
Priority to US11/912,444 priority patent/US7771725B2/en
Priority to BRPI0709452-3A priority patent/BRPI0709452A2/pt
Publication of WO2007118986A2 publication Critical patent/WO2007118986A2/fr
Publication of WO2007118986A3 publication Critical patent/WO2007118986A3/fr
Priority to IL193820A priority patent/IL193820A0/en
Publication of WO2007118986A8 publication Critical patent/WO2007118986A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un nouveau médicament destiné au traitement des arbovirus, à savoir un concentré d' immunoglobulines et de fragments F(ab) '2 et/ou Fab spécifiques dudit arbovirus ainsi que son procédé de préparation.
PCT/FR2007/000560 2006-03-31 2007-04-02 Concentre d'immunoglobulines et de fragments f(ab) '2 et /ou fab specifiques d'un arbovirus en tant que medicament WO2007118986A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP07731238A EP2004229A2 (fr) 2006-03-31 2007-04-02 Concentre d'immunoglobulines et de fragments f(ab) '2 et /ou fab specifiques d'un arbovirus en tant que medicament
JP2009502154A JP2009531400A (ja) 2006-03-31 2007-04-02 医薬品としての、免疫グロブリンとアルボウイルスに特異性を示すＦ（ａｂ）’２及び／又はＦａｂフラグメントの濃縮物、濃縮物の利用、及び濃縮物を調整する方法
AU2007239414A AU2007239414A1 (en) 2006-03-31 2007-04-02 Concentrate of immunoglobulins and F(ab)'2 and/or Fab fragments specific of an arbovirus as medicine
CA002647504A CA2647504A1 (fr) 2006-03-31 2007-04-02 Concentre d'immunoglobulines et de fragments f(ab) '2 et /ou fab specifiques d'un arbovirus en tant que medicament
US11/912,444 US7771725B2 (en) 2006-03-31 2007-04-02 Medicinal concentrate of arbovirus specific immunoglobulins and F(ab)'2 and/or Fab fragments
BRPI0709452-3A BRPI0709452A2 (pt) 2006-03-31 2007-04-02 concetrado de imunoglobulinas e fragmentos f(ab)' 2 e/ou fab especìficos de um arbovìrus como um produto medicinal
IL193820A IL193820A0 (en) 2006-03-31 2008-09-01 Concentrate of immunoglobulins and f(ab)2 and/or fab fragments specific of an arbovirus as medicine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0602803A FR2899112B1 (fr) 2006-03-31 2006-03-31 Concentre d'immunoglobulines et de fragments f (ab)'2 et/ou fab specifiques d'un arbovirus en tant que medicament.
FR0602803 2006-03-31

Publications (3)

Publication Number Publication Date
WO2007118986A2 WO2007118986A2 (fr) 2007-10-25
WO2007118986A3 true WO2007118986A3 (fr) 2007-12-06
WO2007118986A8 WO2007118986A8 (fr) 2010-09-10

Family

ID=37441009

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/000560 WO2007118986A2 (fr) 2006-03-31 2007-04-02 Concentre d'immunoglobulines et de fragments f(ab) '2 et /ou fab specifiques d'un arbovirus en tant que medicament

Country Status (11)

Country Link
US (1) US7771725B2 (fr)
EP (1) EP2004229A2 (fr)
JP (1) JP2009531400A (fr)
KR (1) KR20080110828A (fr)
CN (1) CN101410136A (fr)
AU (1) AU2007239414A1 (fr)
CA (1) CA2647504A1 (fr)
FR (1) FR2899112B1 (fr)
IL (1) IL193820A0 (fr)
TW (1) TW200904472A (fr)
WO (1) WO2007118986A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2899111B1 (fr) * 2006-03-31 2010-09-03 Lab Francais Du Fractionnement Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament.
WO2011124635A1 (fr) 2010-04-07 2011-10-13 Humalys Molécules de liaison au virus du chikungunya et leurs utilisations
EP2374816B1 (fr) 2010-04-07 2016-09-28 Agency For Science, Technology And Research Molécules liant le virus du Chikungunya et leurs utilisations
GB201006753D0 (en) * 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
AR125373A1 (es) * 2021-04-19 2023-07-12 Bharat Serums & Vaccines Ltd ANTICUERPOS POLICLONALES CONTRA SARS-CoV-2 Y SUS APLICACIONES

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919352B2 (en) 2000-12-15 2005-07-19 Smithkline Beecham Corporation Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AGRAWAL AMY GUILLET ET AL: "Human immunoglobulin as a treatment for West Nile virus infection", JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 188, no. 1, 1 July 2003 (2003-07-01), pages 1 - 4, XP002335078, ISSN: 0022-1899 *
BAYRY JAGADEESH ET AL: "Intravenous immunoglobulin for infectious diseases: tailor-made or universal?", THE JOURNAL OF INFECTIOUS DISEASES. 15 NOV 2003, vol. 188, no. 10, 15 November 2003 (2003-11-15), pages 1610; author reply 1610 - 1611, XP002409713, ISSN: 0022-1899 *
BEN-NATHAN D ET AL: "PROPHYLACTIC AND THERAPEUTIC EFFICACY OF HUMAN INTRAVENOUS IMMUNOGLOBULIN IN TREATING WEST NILE VIRUS INFECTION IN MICE", JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 188, no. 1, 1 July 2003 (2003-07-01), pages 5 - 12, XP009069705, ISSN: 0022-1899 *
HAMDAN A ET AL: "POSSIBLE BENEFIT OF INTRAVENOUS IMMUNOGLOBULIN THERAPY IN A LUNG TRANSPLANT RECIPIENT WITH WEST NILE VIRUS ENCEPHALITIS", TRANSPLANT INFECTIOUS DISEASE, MUNKSGAARD, COPENHAGEN, DK, vol. 4, no. 3, September 2002 (2002-09-01), pages 160 - 162, XP009069702, ISSN: 1398-2273 *
KREIL T R ET AL: "Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model.", JOURNAL OF VIROLOGY. APR 1997, vol. 71, no. 4, April 1997 (1997-04-01), pages 2921 - 2927, XP002409714, ISSN: 0022-538X *
KUNISHIGE M ET AL: "Preferential gray matter involvement in dengue myelitis.", NEUROLOGY. 23 NOV 2004, vol. 63, no. 10, 23 November 2004 (2004-11-23), pages 1980 - 1981, XP002409715, ISSN: 1526-632X *
SHIMONI Z ET AL: "TREATMENT OF WEST NILE VIRUS ENCEPHALITIS WITH INTRAVENOUS IMMUNOGLOBULIN", EMERGING INFECTIOUS DISEASES, EID, ATLANTA, GA, US, vol. 7, no. 4, July 2001 (2001-07-01), pages 759, XP009069707, ISSN: 1080-6040 *

Also Published As

Publication number Publication date
WO2007118986A2 (fr) 2007-10-25
CA2647504A1 (fr) 2007-10-25
EP2004229A2 (fr) 2008-12-24
TW200904472A (en) 2009-02-01
FR2899112A1 (fr) 2007-10-05
JP2009531400A (ja) 2009-09-03
WO2007118986A8 (fr) 2010-09-10
IL193820A0 (en) 2011-08-01
AU2007239414A1 (en) 2007-10-25
CN101410136A (zh) 2009-04-15
US20090041780A1 (en) 2009-02-12
FR2899112B1 (fr) 2010-09-03
KR20080110828A (ko) 2008-12-19
US7771725B2 (en) 2010-08-10

Similar Documents

Publication Publication Date Title
WO2007044763A3 (fr) Systeme et procede permettant la detection de transactions frauduleuses
WO2006127757A3 (fr) Fusion interferon-igg
WO2006124713A3 (fr) 4-biarylyl-1-phenylazetidin-2-ones
WO2006078522A3 (fr) Conception de mise sous boitier pour diodes lumineuses
WO2006078530A3 (fr) Modeles de boitiers pour diodes electroluminescentes
WO2004045464A3 (fr) Dispositifs medicaux
EP1847242A4 (fr) Emballage sterile, processus et appareil pour sa production
WO2008060374A3 (fr) Procédés et compositions utiles pour une cicatrisation de plaie chez les diabétiques
WO2007058823A3 (fr) Anticorps anti-egfr
WO2005097832A3 (fr) Anticorps anti-tgf-$g(b) humanises
EP2620450A3 (fr) Compositions d'anticorps anti-CTLA-4
WO2007051164A8 (fr) Modulateurs du recepteur de type toll 3, et leurs procedes et utilisations
WO2007070630A3 (fr) Dispositifs implantables pour guerison acceleree
WO2007062148A3 (fr) Composes chimiques
WO2007001962A3 (fr) Systemes et procedes de production de materiel biologique
WO2007062151A3 (fr) Composes chimiques
WO2007062067A3 (fr) Composes chimiques
WO2007112279A3 (fr) Résonateurs
WO2006110588A8 (fr) Methodes permettant de traiter les troubles cognitifs moderes
WO2007025241A3 (fr) Materiaux chirurgicaux pouvants etre absorbes
WO2007076174A3 (fr) Procédés, systèmes et dispositif pour marqueurs multidomaines
MY154996A (en) Method for conditioning milk, and the products obtained and obtainable therewith
WO2005074645A3 (fr) Procedes et compositions permettant de moduler l'angiogenese
WO2007118986A3 (fr) Concentre d'immunoglobulines et de fragments f(ab) '2 et /ou fab specifiques d'un arbovirus en tant que medicament
WO2006050458A3 (fr) Formes cristallines de tadalafil et leurs procedes de preparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07731238

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 11912444

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 7392/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 193820

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2007239414

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009502154

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2007239414

Country of ref document: AU

Date of ref document: 20070402

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200780011078.1

Country of ref document: CN

Ref document number: 2647504

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007731238

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020087025391

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0709452

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080930